Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Henan Cancer Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1977-01-01

Employees: -

Market Cap: -

Website: http://www.anti-cancer.com.cn

Clinical Trials

Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain

Phase 4

Not yet recruiting

Conditions: Opioid-Induced Constipation
Pain Cancer

Interventions: Drug: Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-release Tablets

First Posted Date: 2025-03-27

Last Posted Date: 2025-03-27

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 203

Registration Number: NCT06897917

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients

Phase 1

Not yet recruiting

Conditions: Breast Cancer
Locally Advanced or Metastatic Breast Cancer

Interventions: Drug: SHR-A1811+ Fulvestrant
Drug: SHR-A1811+ Fulvestrant+HS-10352

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-26

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 52

Registration Number: NCT06788197

Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Phase 2

Active, not recruiting

Conditions: Esophageal Malignant Neoplasm Primary

First Posted Date: 2025-03-21

Last Posted Date: 2025-03-21

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 30

Registration Number: NCT06888531

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

Phase 2

Recruiting

Conditions: HR+/HER2- Breast Cancer

Interventions: Drug: Serplulimab
Drug: Epirubicin
Drug: Albumin Paclitaxel

First Posted Date: 2025-03-06

Last Posted Date: 2025-06-23

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 357

Registration Number: NCT06860529

Locations: 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China

Evaluation of Neoadjuvant Therapy Efficacy and Postoperative Pathological Indicators in Esophageal Cancer Using CT and Multimodal MRI

Not yet recruiting

Conditions: Esophageal Cancer
Neoadjuvant Therapy

First Posted Date: 2025-02-19

Last Posted Date: 2025-02-20

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 400

Registration Number: NCT06833775

SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer

Phase 2

Not yet recruiting

Conditions: TNBC - Triple-Negative Breast Cancer

Interventions: Drug: SHR-A2102 ; Adebrelimab injection

First Posted Date: 2025-02-11

Last Posted Date: 2025-06-23

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 52

Registration Number: NCT06819319

Nab-P+Cb+PD1 Inhibitors Combined/not Combined with Bevacizumab As Neoadjuvant Therapy for Early TNBC

Phase 2

Recruiting

Conditions: Triple-negative Breast Cancer

Interventions: Drug: 6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1)
Drug: 6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1)
Drug: 6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 ( d 1)+5*Bevacizumab ( d 1)
Drug: 6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 ( d 1)+5*Bevacizumab ( d 1)

First Posted Date: 2025-02-10

Last Posted Date: 2025-02-10

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 64

Registration Number: NCT06817525

Locations: 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China

Mechanistic Study on the Diagnosis of Esophageal Cancer Lymph Node Metastasis Using Spectral CT, Multimodal MRI, FAPI PET-CT, Pathology, and AI Evaluation System

Not yet recruiting

Conditions: Esophageal Cancer

First Posted Date: 2025-02-10

Last Posted Date: 2025-02-10

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 400

Registration Number: NCT06818214

Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia

Phase 2

Not yet recruiting

Conditions: SCLC, Extensive Stage

Interventions: Drug: Tislelizumab
Drug: Nanocrystalline Megestrol Acetate
Drug: PTOC

First Posted Date: 2025-01-27

Last Posted Date: 2025-01-27

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 250

Registration Number: NCT06793228

Locations: 🇨🇳
The First Affiliated Hospital of Henan University of Science and Technolog, Luoyang, Henan, China
🇨🇳
Xinxiang Central Hospital, Xinxiang, Henan, China
🇨🇳
Henan cancer hospital,, Zhengzhou, Henan, China

and more 1 locations

Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure

Not yet recruiting

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Sunvozertinib

First Posted Date: 2025-01-22

Last Posted Date: 2025-01-22

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 55

Registration Number: NCT06786208

Locations: 🇨🇳
Qiming Wang, Zhengzhou, Henan, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy